Next-generation sequencing (NGS) assays sequence the genes in human biological samples making them a unique subset of in vitro diagnostic devices (IVDs). Unlike other IVDs, NGS test results determine applicable patient populations, and which genetic variants can affect the authenticity of a test result. This article offers a bulleted list of clinical performance evaluators by which to analyze published clinical trials. Get the article here.
The article is free!
Simply fill in the form below, verify your email address
and you’ll be sent a link to download the article.
Please wait...
Related Posts
- 58By Erica Kramer, Ph.D., Nerac Analyst Originally Published: November 14, 2017 The global in vitro diagnostics (IVD) market was worth about $61.1 billion in 2016 and is projected to grow to $84.6 billion by 2023, with Europe accounting for the second largest market share after North America. The expected market growth, and increased interest in…
- 56Dramatic changes to the regulatory landscape for in vitro diagnostic (IVD) medical devices are in the making. Some of the most impactful changes include a new classification of IVDs, an expansion of post market surveillance and the increased need for Notified Body review. Most medical device manufacturers are aware that failure to meet In Vitro…
- 56By Donna Mitchell-Magaldi, Nerac Analyst Originally Published: February 10, 2015 It is no surprise to anyone in the medical device industry that the European Commission is working on a new regulatory framework that will in essence take the three existing directives: Directive 90/385/EEC regarding active implantable medical devices, Directive 93/42/42 regarding medical devices, and Directive…